In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $43.80 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $43.33, down -1.07%. In other words, the price has decreased by -$1.07 from its previous closing price. On the day, 0.72 million shares were traded. RNA stock price reached its highest trading level at $44.515 during the session, while it also had its lowest trading level at $42.63.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.Barclays initiated its Overweight rating on August 28, 2024, with a $63 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when McCarthy Teresa sold 25,000 shares for $41.14 per share. The transaction valued at 1,028,520 led to the insider holds 94,018 shares of the business.
LEVIN ARTHUR A sold 3,323 shares of RNA for $139,973 on Nov 19 ’24. The Director now owns 14,830 shares after completing the transaction at $42.12 per share. On Nov 06 ’24, another insider, MacLean Michael F, who serves as the Chief Financial Officer of the company, sold 106,319 shares for $45.56 each. As a result, the insider received 4,843,979 and left with 94,093 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5169659392 and an Enterprise Value of 3588680704. For the stock, the TTM Price-to-Sale (P/S) ratio is 505.36 while its Price-to-Book (P/B) ratio in mrq is 3.43. Its current Enterprise Value per Revenue stands at 354.718 whereas that against EBITDA is -11.144.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $5.97. The 50-Day Moving Average of the stock is -4.80%, while the 200-Day Moving Average is calculated to be 21.68%.
Shares Statistics:
The stock has traded on average 1.23M shares per day over the past 3-months and 1408890 shares per day over the last 10 days, according to various share statistics. A total of 119.31M shares are outstanding, with a floating share count of 108.28M. Insiders hold about 9.24% of the company’s shares, while institutions hold 101.08% stake in the company. Shares short for RNA as of 1731628800 were 14516927 with a Short Ratio of 11.81, compared to 1728950400 on 14884198. Therefore, it implies a Short% of Shares Outstanding of 14516927 and a Short% of Float of 15.010001.
